Loading
Loading
Tanning & Pigmentation · 10mg
Janoshik-tested · 10 vials per kit
Melanotan-1 (MT-I) is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) studied in preclinical and clinical research for its pigmentation effects. Research has examined its potential to stimulate melanocytes to produce and distribute melanin, darken skin tone, boost the skin's natural UV defence, and reduce sun-induced damage. As a non-specific melanocortin receptor agonist, studies have also explored its influence on light sensitivity symptoms.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Melanotan I
Afamelanotide
Melanotan I (Afamelanotide) is a linear synthetic analog of α-MSH developed from the same University of Arizona programme as Melanotan II. Unlike MT-2 (cyclic, non-selective), MT-1 is a [Nle4, D-Phe7]-α-MSH analog with substantially greater selectivity for MC1R. It is approved as Scenesse in Europe and Australia for erythropoietic protoporphyria (EPP).
By preferentially activating MC1R on epidermal and follicular melanocytes, afamelanotide stimulates eumelanin production in a sun-independent manner. The resulting melanin deposition provides photoprotection by absorbing UV radiation before it reaches DNA. Greater MC1R selectivity relative to MT-2 means markedly fewer off-target central (MC4R) effects such as spontaneous arousal or nausea.
Clinical data for afamelanotide as Scenesse (an implantable extended-release form) documents protection from phototoxic episodes in EPP patients. Research continues in polymorphous light eruption, acne vulgaris, and vitiligo re-pigmentation. Its superior selectivity profile makes it the preferred compound for photoprotection research. In vitro studies have also shown anti-inflammatory properties at the keratinocyte level.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
